Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 158, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103212
Keywords
Immunotherapy; Non-Hodgkin lymphoma; Mantle cell lymphoma; Systematic review
Categories
Funding
- Janssen
Ask authors/readers for more resources
Mantle cell lymphoma is a rare form of non-Hodgkin's lymphoma with a median overall survival of approximately 3-5 years. Studies have shown that treatment regimens and patient outcomes for MCL can vary based on age and suitability for stem cell transplantation. Despite a lack of directly comparable evidence on the efficacy and safety of MCL therapies, the need for newer treatments to improve patient outcomes is evident.
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median overall survival (OS) of approximately 3-5 years. Systematic literature reviews (SLRs) identified efficacy and safety data for firsttherapies, reported in randomised controlled trials (RCTs) and non-randomised interventional studies (NRISs). Nine and 20 independent studies were included in the RCT and NRISs SLRs, respectively. Differences in regimens and patient outcomes varied according to patient age and suitability for autologous stem cell transplantation (ASCT). In elderly patients ineligible for transplant, OS ranged from 40 months to 69.6 months. young transplant-eligible patients, OS ranged from 53 months to 152.4 months. Despite the paucity of directly comparable evidence on the efficacy and safety of MCL therapies, these SLRs highlight that MCL remains a difficult NHL subtype to treat, with short survival highlighting the unmet need for newer treatments that improve patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available